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Background. Anti-inflammatory and immunomodulatory activities have been reported for maprotiline, a strong norepinephrine
reuptake inhibitor. In addition, some other antidepressant drugs have shown beneficial effects in experimental colitis. Methods.
All the animals were divided into normal and depressed groups. In normal rats colitis was induced by instillation of 2mL of 4%
acetic acid and after 2 hours, maprotiline (10, 20, and 40mg/kg, i.p.) was administered. In reserpinised depressed rats, depression
was induced by injection of reserpine (6mg/kg, i.p.), 1 h prior to colitis induction, and then treated with maprotiline (10, 20,
and 40mg/kg). Treatment continued daily for four days. Dexamethasone (1mg/kg, i.p.) was given as a reference drug. On day
five following colitis induction, animals were euthanized and distal colons were assessed macroscopically, histologically, and
biochemically (assessment of myeloperoxidase activity). Results. Maprotiline significantly improved macroscopic and histologic
scores and diminishedmyeloperoxidase activity in both normal and depressed rats while reserpine exacerbated the colonic damage.
Conclusion. Our data suggests that the salutary effects of maprotiline on acetic acid colitis are probably mediated first through
depressive behavioral changes that could be mediated through the brain-gut axis and second for the anti-inflammatory effect of the
drug.
1. Introduction
The inflammatory bowel diseases (IBD), such as Crohn’s
disease and ulcerative colitis (UC), affect approximately 1-
2 of every 1000 people in developed countries [1]. They
are chronic and relapsing inflammatory disorders of the
gastrointestinal tract defined by clinical characteristics such
as diarrhea, abdominal pains, weight loss, and nausea and
by pathological features such as loss of mucosal integrity
and inflammatory cell infiltration [2]. These chronic diseases
result in serious complications and continue to be a common
cause of morbidity that aggravates the quality of life. Anxiety
and depression are also known to independently affect quality
of life and may additionally impair quality of life in IBD over
and above the IBD itself [3, 4].
Depression and anxiety are significantly more common
among people with IBD than in control population [5–9].The
prevalence of anxiety and/or depression has been estimated
to be as high as 29–35% during remission and 80% for anxiety
and 60% for depression during relapses [10]. The presence of
clinical depression in patients with IBDmay influence disease
activity, aggravate disease symptoms, impact on the evolution
of the disease, andmay affect their response to standard treat-
ment for IBD [11]. Some researchers have further proposed
that anxiety and depression may influence the clinical course
of IBD. They have studied and expressed the contribution
of the psychological disorders to the inflammatory process
in inflammatory bowel disease (IBD) as contribution to
disease onset, to worsening of inflammation and failure of
treatment response, and to relapse of inflammation [12].
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Recent studies have provided strong evidence for plausible
mechanisms by which stress effects could be transduced
into gut inflammation, including stress-induced changes in
intestinal permeability which result in reducing mucosal
barrier function and/or stress-induced changes in mucosal
proinflammatory cytokines which result in exacerbating the
immune dysfunction [13].
Although there are some conflicting results, it has been
suggested that most of the antidepressant drugs, such as
amitriptyline, nortriptyline, imipramine, and doxepin, in
addition to their use for the management of depression, are
broadly used to alleviate various types of pain such as inflam-
matory (rheumatoid arthritis) pain [14–16]. Antidepressants
can also lower the levels of systemic inflammation markers,
such as C-reactive protein and cytokines in many inflam-
matory conditions [17]. Although various classes of antide-
pressants are available for physicians to prescribe, it is clear
from preclinical and clinical data that antidepressant drugs
have no equal anti-inflammatory effect. There are several
reports about the analgesic and anti-inflammatory effects of
antidepressant drugs; for instance, anti-inflammatory activity
of fluoxetine, a selective serotonin reuptake inhibitor (SSRI),
was studied on the carrageenan-induced paw inflammation
in the rat [18]. Antinociceptive and anti-inflammatory effects
of venlafaxine in the rat model of inflammation were eval-
uated and it is shown that pretreatment with venlafaxine
significantly reduced or completely abolished the enhanced
sensitivity to mechanical stimuli provoked by peripheral
carrageenan injection [19]. Additionally anti-inflammatory
effect of amitriptyline [20], fluvoxamine [21], andmaprotiline
[22] on carrageenan-induced paw edema has been evaluated
in our laboratory. Maprotiline is a strong norepinephrine
reuptake inhibitor with weak effects on serotonin and
dopamine reuptake.This drug iswell toleratedwith fewer side
effects and less interferencewith autonomic system compared
with first generation antidepressants [23]. In a recent study
it is shown that both i.p. and i.c.v. maprotiline considerably
decreased paw edema four hours after subplantar injection of
carrageenan [21].
So the present study was designed to investigate the
beneficial effects of maprotiline, a tetracyclic antidepressant,
against acetic acid-induced colitis in normal and reserpinised
depressed rats.
2. Materials and Methods
2.1. Chemicals. The maprotiline was a gift from Razak Phar-
maceutical Company (Tehran, Iran). Dexamethasone was
also a gift from Raha Pharmaceutical Company (Isfahan,
Iran). Reserpine, hexadecyltrimethyl-ammonium bromide
(HTAB), and o-dianisidinedihydrochloride were purchased
from Sigma Chemical Co. (St. Louis, Mo, USA). Formalin
solution 35% w/w, glacial acetic acid, and diethyl ether were
purchased form Merck (Darmstadt, Germany). All other
solvents and chemicals were of analytical grade.
2.2. Animals. Male Wistar rats (200–250 g) were obtained
from the animal house of the School of Pharmacy, Isfahan
University of Medical Sciences, Iran. Rats were fasted for
24 h before induction of colitis in stainless steel cages with
free access to water. During experiment, the animals were
housed in standard polypropylene cages, four per cage, under
a 12:12 h light/dark cycle with free access to food and water.
The experiments were carried out in accordance with local
guidelines for the care of laboratory animals of the Isfahan
University of Medical Sciences.
2.3. Behavioral Tests
2.3.1. Determination of Antidepressant Dose of Maprotiline in
Reserpinised Depressed Rats. Thirty-six rats were randomly
divided into the following groups of six rats in each. Sham
group received intraperitoneally (i.p.) injection of normal
saline daily for four days; control group received reserpine
(6mg/kg, i.p.) at the first day and daily normal saline for four
days; and test groups received reserpine (6mg/kg, i.p.) at the
first day and daily maprotiline (5, 10, 20, and 40mg/kg, i.p.)
for four days.
At the third day, the rats were individually placed in
a cylinder containing water 15 cm in height at 25∘C for
15min. On the following day (fourth day) the rats were again
immersed in water and total duration of immobility was
measured for 5min.The immobility time was regarded as the
time the mouse spent floating in the water without struggling
andmaking only thosemovements necessary to keep its head
above water (forced swimming test) [24].
2.4. Induction of Experimental Colitis. Distal colitis was
induced by intracolonic instillation of 2mL of acetic acid (4%
v/v in 0.9% saline) according to MacPherson and Pfeiffer’s
method [25]. After 24 h fasting, each rat was lightly anes-
thetized with ether and a polypropylene catheter was inserted
into the colon via the anus.The catheter was advanced so that
the tip was 8 cm proximal to the anus. At this point acetic acid
was instilled. Then the rat was kept in a head-down position
for 30 s to limit expulsion of the solution.
2.5. Experimental Groups. Animals were randomly divided
into the following groups each consisting of six. Sham
group underwent the cannulation procedure without col-
itis induction, receiving normal saline instead of acetic
acid. Control group received normal saline (1mL/kg, i.p.),
respectively, after induction of colitis. Test groups included
nonreserpine treated groups which received maprotiline (10,
20, and 40mg/kg, i.p.) and reserpine treated groups (6mg/kg,
i.p.), 1 h prior to induction of colitis and then treated with
maprotiline (10, 20, and 40mg/kg, i.p.), and reference group
which received dexamethasone (1mg/kg, i.p.) after induction
of colitis.
All treatments were carried out 2 h after colitis induction
and continued daily for four days.
2.6. Measurement of Body Weight Changes. Body weight was
recorded for each animal during the experimental period
(prior to induction of colitis and subsequently daily over the
test period).
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2.7. Evaluation of Colon Macroscopic Damage. Rats were
euthanized by an overdose of ether anesthesia at the fifth
day (the day after receiving the last dose). Abdomen was
opened and colon was exposed. Distal colon, 8 cm in length
and 2 cm proximal to the anus, was excised and opened
longitudinally. The tissue of colon was rinsed with normal
saline and wet weight was measured [26]. Then, the tissue
was fixed on a white plastic sheet and a photo was taken
using an appropriately adjusted Nikon camera (Coolpix
p100). Macroscopic damage scores were assigned by an
independent observer according to the following criteria: 0 =
no macroscopic changes, 1 = mucosal erythema only, 2 =
mild mucosal edema, slight bleeding, or slight erosion, 3 =
moderate edema, bleeding ulcers, or erosions, and 4 = severe
ulceration, erosions, edema, and tissue necrosis [27]. Fur-
thermore, ulcer area was measured by Fiji-win 32 software,
an image processing and analysis software inspired by NIH
image for the Macintosh [28]. For each specimen ulcer index
was calculated using the following equation [29]:
Ulcer Index = Ulcer area (Cm2) +Macroscopic score.
(1)
After that, the colon specimen was bisected in the middle
equally. One part was frozen in liquid nitrogen and kept
at freezer (−74∘C) in order to measure the myeloperoxidase
(MPO) enzyme activity. Another part was fixed in 10% for-
malin solution in phosphate buffered saline for pathological
examination [30].
2.8. Evaluation of Colon Histological Damage. To process
for histopathological studies, colonic specimens which were
fixed in 10% formalin in phosphate buffered saline embedded
in paraffin and cut into 4 𝜇m sections. Then paraffin sections
were deparaffinized with xylene and then hydrated and
stained with hematoxylin and eosin (H&E). The stained sec-
tions were assessed for any inflammatory changes including
infiltration of cells, necrosis, or damage to tissue structures
[31]. Inflammation severity and extent aswell as crypt damage
were evaluated on H&E stained according to the criteria
previously described by Dieleman et al. [32]. Total colitis
index was measured by summing these three subscores
(inflammation severity, inflammation extent, and crypt dam-
age).
2.9.MyeloperoxidaseAssay. Myeloperoxidase (MPO) enzyme
activity, a marker of neutrophil infiltration, was measured in
colon tissue according to the modified method of Bradley et
al. [33]. The colon tissue was weighed and homogenized in
1mL of 50mM potassium phosphate solution (pH: 6) with
0.5% HTAB and 5mM EDTA in an ice bath using polytron
homogenizer. Additional buffer solution was added to obtain
a concentration equivalent to 5mL per 0.1 g of colon tissue.
The resultant homogenate was sonicated in an ice bath for
10 s, then subjected to a sequence of freezing and thawing 3
times, and sonicated again for 10 s and centrifuged for 15min
at 15,000 rpm at 4∘C. An aliquot of 0.1mL of the supernatant
was mixed with 2.9mL of 50mM phosphate buffer (pH: 6)
containing 0.167mg/mL o-dianisidinedihydrochloride and
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Figure 1: Effect of maprotiline (5, 10, 20, and 40mg/kg, i.p.) on
duration of immobility (seconds) during forced swimming test
in reserpinised (6mg/kg, i.p.) rats. RSP: reserpine (6mg/kg); i.p.:
intraperitoneally. Results are expressed as mean ± SEM of six rats
in each group. ∗∗∗𝑃 < 0.001 compared to RSP; one-way ANOVA
followed by Tukey’s test.
0.0005% hydrogen peroxide. The change in absorbance at
460 nm was measured using a UV-Vis spectrophotometer
(LSI Model, Alfa-1502).
2.10. Statistical Analysis. Results are expressed as means ±
SEM for parametric and median (range) for nonparametric
data and the minimum level of significance was considered
at 𝑃 < 0.05. All statistical analyses were assessed using
GraphPad Prism 5 software. Differences among groups were
tested by parametric one-way analysis of variance (ANOVA)
with Tukey’s HSD as post hoc test. Nonparametric data were
analyzed using Kruskal-Wallis followed by Mann-Whitney U
test.
3. Results
3.1. Behavioral Tests
3.1.1. Assessment of Antidepressant Dose of Maprotiline Using
Forced Swimming Test. As it is shown in Figure 1, maprotiline
at doses of 10, 20, and 40mg/kg significantly reduced the time
spent immobile compared to reserpine group (𝑃 < 0.001). So
these three doses of maprotiline were selected for evaluation
in the ulcerative colitis rats.
3.2. Animals’ Body Weight Loss. Twenty-four hours after the
instillation of 4% acetic acid into the colon, the animals
developed bloody diarrhea, weakness, and decreased food
intake that resulted in bodyweight loss during the experiment
period. Tables 1 and 2 summarize the data of body weight loss
of Sham, control, and treatment groups.
As illustrated in Tables 1 and 2 control group showed
loss of body weight on day five (𝑃 < 0.01) whereas
i.p. injection of maprotiline reduced this body weight loss
in nondepressed rats. In reserpine-induced (6mg/kg, i.p.)
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Table 1: Effect of maprotiline (Map. 10, 20, and 40mg/kg) on changes in the body weight in the indicated conditions.
Group Sham Control Dex. 1 Map. 10 Map. 20 Map. 40
Body weight changes after four days (g) 8.8 ± 2.3 −22.5 ± 5.3∗∗ 0.3 ± 5.1 −13.67 ± 9.1 5.5 ± 6.5 1.0 ± 6.3
Dex. 1: dexamethasone (1mg/kg); i.p.: intraperitoneally. Results are expressed as mean ± SEM of six rats in each group. ∗∗𝑃 < 0.01 compared to Sham group;
one-way ANOVA followed by Tukey’s test.
Table 2: Effect of maprotiline (Map. 10, 20, and 40mg/kg) on changes in the body weight in the indicated conditions.
Group Sham Control Dex. 1 RSP Map. 10 Map. 20 Map. 40
Body weight changes after four days (g) 8.8 ± 2.3 −22.5 ± 5.3∗∗ 0.3 ± 5.1 −30.2 ± 2.8∗∗∗ −18.7 ± 5.1∗ −7.3 ± 6.8 −13.5 ± 3.1
Dex. 1: dexamethasone (1mg/kg), RSP: reserpine (6mg/kg), and i.p.: intraperitoneally. Animals were also reserpinised (6mg/kg, i.p.) depressed. Results are
expressed as mean ± SEM of six rats in each group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 compared to Sham group; one-way ANOVA followed by Tukey’s
test.
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Figure 2: Effect of maprotiline (10, 20, and 40mg/kg, i.p.) on weight of distal colon. (a) Normal rats and (b) reserpinised (6mg/kg, i.p.)
depressed rats. i.p.: intraperitoneally, Dex. 1: dexamethasone (1mg/kg), and RSP: reserpine (6mg/kg). Results are expressed as mean ± SEM
of six rats in each group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 compared to control; one-way ANOVA followed by Tukey’s test.
depressed animals, control, reserpine (RSP, 6mg/kg), and
maprotiline (10mg/kg) groups experienced a significant loss
of body weight in comparison with Sham group. Additionally
there is no significant difference between maprotiline at
doses of 20, 40mg/kg, dexamethasone, and Sham group in
depressed and nondepressed rats.
3.3. Macroscopic Assessment. To assess the effect of maproti-
line on macroscopic features in the rat model of colitis, two
parameters including colon wet weight and ulcer index were
evaluated in both normal and reserpinised (6mg/kg, i.p.)
depressed rats. In nondepressed animals, induction of colitis
caused severe inflammation, ulceration, dilatation, adhesion,
and wall thickening whereas colons of Sham group were
normal (𝑃 < 0.001) (Figures 2 and 3).
In reserpinised depressed rats there was no significant
difference between the reserpine (RSP, 6mg/kg) group and
control by considering both weight of colon and ulcer index
(Figures 2(b) and 3(b)). So weight of colon tissue, ulcer index,
and the severity of lesion with necrosis in group receiving
reserpine (RSP, 6mg/kg, i.p.) were increased. As expected,
the reference drug, dexamethasone (1mg/kg), caused a sig-
nificant decrease in weight of colon and ulcer index in both
normal and depressed rats (Figures 2 and 3). As it is shown in
Figure 2, i.p. injection ofmaprotiline at doses of 20mg/kg and
40mg/kg significantly reduced the weight of colon in both
normal and depressed rats.
As illustrated in Figure 3(a), i.p. injection of maprotiline
at doses of 20mg/kg (𝑃 < 0.01) and 40mg/kg (𝑃 < 0.001)
significantly and dose-dependently attenuated ulcer index as
compared to control in nondepressed rats.
3.4. Assessment of Myeloperoxidase Activity. Colonic injury
following acetic acid administration was accompanied by
increased MPO activity, indicating neutrophil infiltration in
inflamed tissue. As can be noted in Figure 4(b), there was a
significant increase in colonic MPO activity in control and
reserpine (RSP, 6mg/kg) groups as compared to Sham. In
reserpinised (6mg/kg, i.p.) depressed rats, treatment with
reserpine as a depressing agent significantly brought about
a high MPO activity level same as that of control group.
Conversely maprotiline treatment at dose of 20mg/kg (𝑃 <
0.01) and 40mg/kg (𝑃 < 0.001) and dexamethasone
treatment (𝑃 < 0.001) significantly diminished the MPO
activity level in nondepressed rat (Figure 4(a)). Additionally,
in reserpine-induced depressed rats, maprotiline at dose of
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Figure 3: Effect of maprotiline (10, 20, and 40mg/kg, i.p.) on ulcer index. (a) Normal rats and (b) reserpinised (6mg/kg, i.p.) depressed rats.
i.p.: intraperitoneally, Dex. 1: dexamethasone (1mg/kg), and RSP: reserpine (6mg/kg). Results are expressed as mean ± SEM of six rats in
each group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 compared to control; one-way ANOVA followed by Tukey’s test.
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Figure 4: Effect of maprotiline (10, 20, and 40mg/kg, i.p.) on myeloperoxidase (MPO) enzyme activity in the colonic tissue. (a) Normal rats
and (b) reserpinised (6mg/kg, i.p.) depressed rats. i.p.: intraperitoneally, Dex. 1: dexamethasone (1mg/kg), and RSP: reserpine (6mg/kg).
Results are expressed as mean ± SEM of six rats in each group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 compared to control; one-way
ANOVA followed by Tukey’s test.
40mg/kg reduced the MPO activity level significantly (𝑃 <
0.05) (Figure 4(b)).
3.5. Pathological Assessment of the Colon. Colonic mucosa of
rats in Sham group had a normal architecture with intact
epithelium (Figure 5). Pathologic assessment of colon in
control group and reserpine (RSP, 6mg/kg) group showed
multifocal areas of necrosis, hemorrhage, submucosal edema,
and inflammatory cell infiltration in lamina propria as well
as loss of epithelium integrity (Figure 5). Administration
of dexamethasone as reference and maprotiline at doses of
20, 40mg/kg significantly attenuated the histopathological
changes in both normal and reserpine-induced depressed rats
(Table 3). Reepithelization of the mucosal layer and reduced
inflammatory cell infiltration in propria were observed in
these groups.
4. Discussion
The results of the present study clearly demonstrate that
four days of administration of maprotiline, a tetracyclic
antidepressant drug, at doses of 10, 20, and 40mg/kg reduced
the immobility time in forced swimming test in reserpinised
(6mg/kg, i.p.) depressed rats. Maprotiline also improved
acetic acid-induced colitis in normal and reserpine-induced
depressed rats. Administration of maprotiline as an antide-
pressant drug significantly decreased body weight loss and
also increased body weight in normal rats. Biochemical
and histological results also confirmed the effectiveness of
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Table 3: Effect of maprotiline (Map. 10, 20, and 40mg/kg, i.p.) on pathologic parameters of colitis induced by acetic acid in normal and
reserpinised (6mg/kg, i.p.) depressed rats.
Groups Inflammation severity (0–3) Inflammation extent (0–3) Crypt damage (0–4) Total colitis index (0–10)
Sham 0 (0-0)∗∗ 0 (0-0)∗∗ 0 (0-0)∗∗ 0 (0-0)∗∗
Control 3 (2-3) 3 (2-3) 4 (1–4) 9.5 (6–10)
Dex. 1 0.5 (0-1)∗∗ 0 (0–2)∗∗ 0 (0–2)∗∗ 1 (0–5)∗∗
Map. 10 2 (0–3) 2.5 (0–3) 3 (0–4) 7.5 (0–9)
Map. 20 1 (0-1)∗ 1 (0–2)∗∗ 1 (0-1)∗ 3 (0–4)∗∗
Map. 40 1 (0-1)∗∗ 1 (0–2)∗∗ 0 (0-0)∗∗ 2 (0–3)∗∗
RSP 3 (1–3) 3 (1–3) 4 (1–4) 10 (4–10)
RMAP10 2.5 (1–3) 2 (1–3) 3 (0–4) 7.5 (2–10)
RMAP20 1 (1-1)∗ 1 (0–2)∗ 1.5 (0-0)∗ 4.5 (1–3)∗∗
RMAP40 1 (0–3)∗∗ 1 (0–3)∗∗ 0.5 (0-1)∗ 3 (0–7)∗∗
Dex. 1: dexamethasone (1mg/kg), RSP: reserpine (6mg/kg), i.p.: intraperitoneally. Values are presented as median (range) of six rats in each group. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01 compared to control; Mann-Whitney𝑈 test.
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 5: Histological appearances of colonic tissues in rats (H&E staining; magnification ×10). (a) Normal intactmucosa from Sham animals
showed intact epithelial surface. (b) Colitis induced by acetic acid in control group: crypt damage, mucosal layers destruction, and leukocyte
infiltration are evident. (c) acetic acid-induced colitis in reserpinised (6mg/kg, i.p.) depressed rat, showing massive necrotic destruction of
epithelium. (d, g, and h)Colitis tissue treatedwith dexamethasone (1mg/kg, i.p.),maprotiline (20mg/kg, i.p.), andmaprotiline (40mg/kg, i.p.)
in nondepressed rats, respectively. (e, f) Colitis tissue treated withmaprotiline (20mg/kg, i.p.) andmaprotiline (40mg/kg, i.p.) in reserpinised
(6mg/kg, i.p.) depressed rats, showing attenuated the extent and severity of the histological signs of cell damage. i.p. = intraperitoneally.
maprotiline in improving acetic acid-induced colitis both in
normal and reserpinised animals.
It is not deniable that people with inflammatory bowel
disease (IBD) in general practice suffer from depression or
anxiety as a reaction to living with this disease [34, 35]. On
the other hand, it is believed that both depression and anxiety
may also precede people with IBD through increasing per-
meability of colonic mucosa or increasing proinflammatory
cytokines [36].
Despite the potential for anxiety and depression to play an
important role in the clinical course of IBD, and despite the
widespread antidepressant drugs, but according to available
data, there is no any study to introduce a specific antide-
pressant drug which in addition to treating psychological
disorders has beneficial effect in clinical course of IBD. So,
for the first time, this paper reports the beneficial effect of
maprotiline on experimental colitis in normal and reserpine-
induced depressed rats.
It is evident that the immune system can fundamentally
change in those suffering from major psychiatric disorders
such as depression and anxiety disorders [37]. These mood
disorders can stimulate production of proinflammatory
cytokines and thereby adversely affect the course of IBD [36].
It is, therefore, a priority to pay careful attention to the possi-
bility of mood disorders in patients with IBD. In the present
study forced swimming test (FST) as a well-established
animal test [24, 38] was used to evaluate reserpine-induced
depression through increasing the duration of immobility
time and also maprotiline by decreasing the duration of
immobility time. This model is a valid model for evaluating
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depressive or antidepression effects [39, 40]. It is worth
mentioning that maprotiline shows a strong antagonism
against reserpine-induced effects in animal studies, as do
the other classical antidepressants. Our result showed that
reserpine (6mg/kg, i.p.) significantly (𝑃 < 0.01) increased
immobility time in FST as compared to control group
and maprotiline (10, 20, and 40mg/kg, i.p.) significantly
(𝑃 < 0.001) antagonized reserpine-induced increase in mean
immobility time in FST (Figure 1).
Acetic acid-induced colitis is an easily inducible model
of IBD, and the similarity of the inflammatory mediators
profile to IBD suggests that the inflammatory phase bears
some resemblance to human intestinal inflammation. Intra-
colonic instillation of 4% acetic acid causes a relatively bland
epithelial necrosis and edema that variably extended into the
lamina propria, submucosa, or externalmuscle layers [41, 42].
In the present study dexamethasone is used as reference
drug to compare the efficacy of treatment drugs on colitis
and the results showed protection considering macroscopic
and microscopic factors for applied drugs. In reserpinised
depressed rats with no treatment (RSP group) we observed
that colitis situation was exacerbated and epithelial necrosis
and edema as well as body weight loss were exacerbated. But
in groups which have received maprotiline both colitis status
and body weight loss were improved.
There is a richly innervated nerve plexus between the
enteric nervous system (ENS) and its spinal and autonomic
connections to the central nervous system, known as the
brain-gut axis. GI motor, sensory, and secretory functions as
well as thresholds for the perception of pain can be affected
by psychological disorders and emotional stress directly or
indirectly through this axis. These effects are mediated by
substance P (SP), vasoactive intestinal protein (VIP), several
neuropeptides, neurotransmitters, and hormones [13]. In
the present study depressive symptoms which are induced
in reserpine-treated rats resulted in reduced food intake,
weight loss, and exacerbation ofmacroscopic and histological
features of colitis. Conversely improvement of the depressive
symptoms by administration of maprotiline as an antide-
pressant possibly through the brain-gut axis improved food
intake and other colitis parameters [43]. So maprotiline at
doses of 20 and 40mg/kg which showed antidepressant effect
as confirmed by forced swimming test caused a dramatic
reduction in the severity of colitis as indicated by improved
macroscopic and histological features of IBD.
Reducing food intake with bloody diarrhea just twenty-
four hours after induction of colitis is a convincing reason
for weight loss in control group. Muscat et al. [44] reported
that depression and chronic stress reduced the consumption
of palatable sweet solution and weight loss such that this
effect reversed by treatment with fluoxetine and maprotiline.
As illustrated in Tables 1 and 2 depressions exacerbate body
weight loss in reserpinised depressed rats and this effect
reversed by administration of maprotiline.
During the inflammatory disease MPO content in the
target tissue is increased and it is also augmented in both
experimental and human IBD [45]. In this study, MPO activ-
ity in reserpine (RSP, 6mg/kg) group as well as control group
was markedly elevated showing that neutrophil infiltration
to the inflamed tissue is increased following induction of
colitis. Following five days treatment, maprotiline at doses
of 20, 40mg/kg diminished the elevated amounts of this
biochemical marker in normal and depressed rats. According
to pathological examination our result showed a marked
reduction in the infiltration of PMN leucocytes into the
inflamed colonic tissue compared to control (Table 3).
There is a bidirectional communication between neurons
and mast cells within the gastrointestinal tract [36]. Dvorak
and colleagues [46] reported that the number of mast cells
was markedly increased in the involved area of the ileum of
patients with IBD. Furthermore mucosal mast cells can be
activated by stress and other psychological disorders. Acti-
vation of mast cells following neurological diseases such as
depression, through release of mediators such as eicosanoids,
serotonin, and IL-6, could contribute to the pathogenesis of
IBD [47].
It has been shown that hypothalamus-pituitary-adrenal
(HPA) axis function is reduced in patients with IBD; this
observation may be relevant to stress induced increases in
disease activity. Also, it has recently been demonstrated
that reduced HPA axis function renders rodents susceptible
to stress-induced increases in gastrointestinal inflammation
[36]. In the present study maybe it is why depressed animal
showed an increased susceptibility to acetic acid-induced
colitis (reserpinised groups), an effect which was found to be
dependent on coexisting stress.
It has been reported that anti-inflammatory effect of
antidepressants is mediated through improving HPA func-
tion or inhibition of SP [18]. Ghia et al. reported that
antidepressants can improve the autonomic dysfunction in
IBD patients, thereby inhibiting proinflammatory mediator
release [48]. So in the present study we hypothesized that
maprotiline-induced alleviation of intestinal inflammation
might be through reduction of these inflammatorymediators.
Another possible mechanism is the direct stimulatory effect
of maprotiline on cortisol secretion or indirect increase of
this anti-inflammatory hormone via hypothalamic-pituitary-
adrenal axis. However, reaching a definite mechanism needs
further studies.
Antidepressants have been shown to inhibit the activation
of gene expression of iNOS (inducible nitric oxide synthase)
and various proinflammatory cytokine through indirect acti-
vation of monoamine receptors and the cAMP/PKA pathway
in immune cells and/or direct effect on mast cells and other
immune cells [49]. In conclusion, maprotiline is likely to
reduce the proinflammatory cytokine and NO release from
immune intestinal cells through this plausible mechanism.
Enhanced histamine levels are common in the mucosa
and intestinal secretions of patients with IBD [50, 51]. Since
maprotiline in doses that significantly inhibit the neuronal
uptake of noradrenaline causes a marked inhibition of his-
tamine [52], it may be suggested that this beneficial effect in
the treatment of colitis is to some extent due to interaction
with histamine.
In summary, our results confirm and extend our knowl-
edge about anti-inflammatory effect of maprotiline on
acetic acid-induced colitis in both normal and reserpinised
8 International Scholarly Research Notices
depressed rats. Although depressive disorders are more com-
mon in such chronic disease and can exacerbate the clinical
course of IBD, treatment of depression by an antidepressant
drug which has beneficial effect in the course of underlying
disease invokes the proverb “kill two birds with one stone.”
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